Fibroblast Growth Factors

• 

  Subject Areas on Research

  • (1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. 
  • A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. 
  • A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. 
  • A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. 
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. 
  • A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. 
  • A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. 
  • A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. 
  • Acid Load and Phosphorus Homeostasis in CKD. 
  • Acidic fibroblast growth factor enhances peripheral nerve regeneration in vivo. 
  • Acidic fibroblast growth factor enhances regeneration of processes by postnatal mammalian retinal ganglion cells in culture. 
  • Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. 
  • Activation of fibroblast growth factor (FGF) receptors by recombinant human FGF-5. 
  • Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. 
  • An FGF autocrine loop initiated in second heart field mesoderm regulates morphogenesis at the arterial pole of the heart. 
  • An interaction between the III-IV linker and CTD in NaV1.5 confers regulation of inactivation by CaM and FHF. 
  • Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. 
  • Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. 
  • BMP signaling in the epiblast is required for proper recruitment of the prospective paraxial mesoderm and development of the somites. 
  • Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study. 
  • Bmp signaling regulates proximal-distal differentiation of endoderm in mouse lung development. 
  • Bmp4 and Fgf10 play opposing roles during lung bud morphogenesis. 
  • Branching out: origins of the sea urchin larval skeleton in development and evolution. 
  • Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. 
  • Case report: aplasia of the lacrimal and major salivary glands (ALSG). 
  • Casein kinase 1 regulates Sprouty2 in FGF-ERK signaling. 
  • Characterization of the murine BEK fibroblast growth factor (FGF) receptor: activation by three members of the FGF family and requirement for heparin. 
  • Chordin and noggin promote organizing centers of forebrain development in the mouse. 
  • Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. 
  • Comparison of the expression of three highly related genes, Fgf8, Fgf17 and Fgf18, in the mouse embryo. 
  • Conditional knockout of Fgf13 in murine hearts increases arrhythmia susceptibility and reveals novel ion channel modulatory roles. 
  • Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates. 
  • Coronary artery disease and the thrombospondin single nucleotide polymorphisms. 
  • Correlates of left ventricular mass in chronic hemodialysis recipients. 
  • Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. 
  • Crystal structure of the ternary complex of a NaV C-terminal domain, a fibroblast growth factor homologous factor, and calmodulin. 
  • Current view on regulation of voltage-gated sodium channels by calcium and auxiliary proteins. 
  • Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. 
  • Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. 
  • Dietary factors and fibroblast growth factor-23 levels in young adults with African ancestry. 
  • Disordered FGF23 and mineral metabolism in children with CKD. 
  • Disorders of phosphorus homeostasis. 
  • Disruption of Fgf13 causes synaptic excitatory-inhibitory imbalance and genetic epilepsy and febrile seizures plus. 
  • Distinct mesodermal signals, including BMPs from the septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm. 
  • Distinct requirements for extra-embryonic and embryonic bone morphogenetic protein 4 in the formation of the node and primitive streak and coordination of left-right asymmetry in the mouse. 
  • Divide, multitask, and conquer: Coordination in channel regulation. 
  • Does a rise in plasma erythropoietin after high-altitude exposure affect FGF23 in healthy volunteers on a normal or low-phosphorus diet? 
  • Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. 
  • Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. 
  • Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. 
  • Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. 
  • Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. 
  • Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. 
  • Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. 
  • Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. 
  • Effects of keratinocyte growth factor-2 (KGF-2) on wound healing in an ischaemia-impaired rabbit ear model and on scar formation. 
  • Effects of phosphate binders in moderate CKD. 
  • Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. 
  • Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury. 
  • Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. 
  • Emergence of the keratinocyte growth factor multigene family during the great ape radiation. 
  • Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. 
  • Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease. 
  • Evidence basis for integrated management of mineral metabolism in patients with end-stage renal disease. 
  • Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. 
  • Evidence that autocrine signaling through Bmpr1a regulates the proliferation, survival and morphogenetic behavior of distal lung epithelial cells. 
  • Evolution and development of the mammalian dentition: insights from the marsupial Monodelphis domestica. 
  • Evolving revascularization approaches for myocardial ischemia. 
  • Exposure to organophosphates reduces the expression of neurotrophic factors in neonatal rat brain regions: similarities and differences in the effects of chlorpyrifos and diazinon on the fibroblast growth factor superfamily. 
  • Expression and possible function of fibroblast growth factor 9 (FGF9) and its cognate receptors FGFR2 and FGFR3 in postnatal and adult retina. 
  • Expression of bone morphogenetic protein-4 (BMP-4), bone morphogenetic protein-7 (BMP-7), fibroblast growth factor-8 (FGF-8) and sonic hedgehog (SHH) during branchial arch development in the chick. 
  • Expression of fgf23 and αklotho in developing embryonic tissues and adult kidney of the zebrafish, Danio rerio. 
  • Expression of growth factor and growth factor receptor RNA in rat pleural mesothelial cells in culture. 
  • FGF signaling regulates rod photoreceptor cell maintenance and regeneration in zebrafish. 
  • FGF signals guide migration of mesenchymal cells, control skeletal morphogenesis [corrected] and regulate gastrulation during sea urchin development. 
  • FGF-23 levels in patients with AKI and risk of adverse outcomes. 
  • FGF-23: More than a regulator of renal phosphate handling? 
  • FGF12 is a candidate Brugada syndrome locus. 
  • FGF13 modulates the gating properties of the cardiac sodium channel Nav1.5 in an isoform-specific manner. 
  • FGF14 modulates resurgent sodium current in mouse cerebellar Purkinje neurons. 
  • FGF14 regulates presynaptic Ca2+ channels and synaptic transmission. 
  • FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity. 
  • FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults: The CARDIA Study. 
  • FGF23 and Left Ventricular Hypertrophy in Children with CKD. 
  • FGF23 and Nutritional Metabolism. 
  • FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. 
  • FGF23 in chronic kidney disease. 
  • FGF23 induces left ventricular hypertrophy. 
  • FGF23 modifies the relationship between vitamin D and cardiac remodeling. 
  • FGF23 or PTH: which comes first in CKD ? 
  • FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. 
  • FGF23: fashion or physiology? 
  • Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. 
  • Fgf signaling instructs position-dependent growth rate during zebrafish fin regeneration. 
  • Fgf-dependent depletion of microRNA-133 promotes appendage regeneration in zebrafish. 
  • Fgf9 induces proliferation and nuclear localization of FGFR2 in Sertoli precursors during male sex determination. 
  • Fgfs control homeostatic regeneration in adult zebrafish fins. 
  • Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. 
  • Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study. 
  • Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study. 
  • Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. 
  • Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study. 
  • Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study. 
  • Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. 
  • Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. 
  • Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. 
  • Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. 
  • Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function. 
  • Fibroblast Growth Factor Homologous Factors: New Roles in Neuronal Health and Disease. 
  • Fibroblast Growth Factor-23 (FGF-23) Levels Differ Across Populations by Degree of Industrialization. 
  • Fibroblast Growth Factor-23 Fans the Flames of Heart and Kidney Failure. 
  • Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study. 
  • Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. 
  • Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. 
  • Fibroblast growth factor 21 and thyroid hormone show mutual regulatory dependency but have independent actions in vivo. 
  • Fibroblast growth factor 21 mediates specific glucagon actions. 
  • Fibroblast growth factor 23 and Inflammation in CKD. 
  • Fibroblast growth factor 23 and incident CKD in type 2 diabetes. 
  • Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. 
  • Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. 
  • Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. 
  • Fibroblast growth factor 23 and the future of phosphorus management. 
  • Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. 
  • Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. 
  • Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. 
  • Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. 
  • Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. 
  • Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. 
  • Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. 
  • Fibroblast growth factor homologous factor 13 regulates Na+ channels and conduction velocity in murine hearts. 
  • Fibroblast growth factor homologous factors in the heart: a potential locus for cardiac arrhythmias. 
  • Fibroblast growth factor homologous factors modulate cardiac calcium channels. 
  • Fibroblast growth factor homologous factors tune arrhythmogenic late NaV1.5 current in calmodulin binding-deficient channels. 
  • Fibroblast growth factor signaling in the developing tracheoesophageal fistula. 
  • Fibroblast growth factor-23 and cardiovascular events in CKD. 
  • Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. 
  • Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. 
  • Fibroblast growth factor-23-mediated inhibition of renal phosphate transport in mice requires sodium-hydrogen exchanger regulatory factor-1 (NHERF-1) and synergizes with parathyroid hormone. 
  • Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes. 
  • Fluorescence in situ hybridization analysis of keratinocyte growth factor gene amplification and dispersion in evolution of great apes and humans. 
  • Forging forward with 10 burning questions on FGF23 in kidney disease. 
  • Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action. 
  • GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease. 
  • Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. 
  • Gene-gene interaction between FGF20 and MAOB in Parkinson disease. 
  • Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. 
  • Genetic background influences cardiac phenotype in murine chronic kidney disease. 
  • Genome-wide meta-analysis of macronutrient intake of 91,114 European ancestry participants from the cohorts for heart and aging research in genomic epidemiology consortium. 
  • Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. 
  • Growth factors for therapeutic angiogenesis in peripheral arterial disease. 
  • Haptotactic gradients for directed cell migration: stimulation and inhibition using soluble factors. 
  • Hedgehog inhibits β-catenin activity in synovial joint development and osteoarthritis. 
  • Heterochrony in somitogenesis rate in a model marsupial, Monodelphis domestica. 
  • High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. 
  • Hypophosphatemic rickets in opsismodysplasia. 
  • Identification and requirements of enhancers that direct gene expression during zebrafish fin regeneration. 
  • Identification of novel interaction sites that determine specificity between fibroblast growth factor homologous factors and voltage-gated sodium channels. 
  • Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry. 
  • Increased expression of fibroblast growth factors in a rabbit skeletal muscle model of exercise conditioning. 
  • Inducible Fgf13 ablation enhances caveolae-mediated cardioprotection during cardiac pressure overload. 
  • Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. 
  • Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. 
  • Is FGF13 a major contributor to genetic epilepsy with febrile seizures plus? 
  • KLB is associated with alcohol drinking, and its gene product β-Klotho is necessary for FGF21 regulation of alcohol preference. 
  • Keratinocyte growth factor--just another mitogen or the "Holy Grail" that regulates liver regeneration? 
  • Kidney to bone via bedside to bench…and back? 
  • Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia. 
  • Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. 
  • Knockout of the X-linked Fgf13 in the hypothalamic paraventricular nucleus impairs sympathetic output to brown fat and causes obesity. 
  • Laser-assisted delivery of vitamin C, vitamin E, and ferulic acid formula serum decreases fractional laser postoperative recovery by increased beta fibroblast growth factor expression. 
  • Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. 
  • Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. 
  • Maintenance of blastemal proliferation by functionally diverse epidermis in regenerating zebrafish fins. 
  • Male-to-female sex reversal in mice lacking fibroblast growth factor 9. 
  • Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. 
  • Mineral metabolites and CKD progression in African Americans. 
  • Mixed signals: development of the testis. 
  • Morphogenesis. 
  • Msx1 and Pax3 cooperate to mediate FGF8 and WNT signals during Xenopus neural crest induction. 
  • NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. 
  • NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. 
  • Nephropathic Cystinosis: A Distinct Form of CKD-Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23. 
  • Neurogenesis in the sea urchin embryo is initiated uniquely in three domains. 
  • Neuronal regulation of the spatial patterning of neurogenesis. 
  • Novel role for Netrins in regulating epithelial behavior during lung branching morphogenesis. 
  • Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. 
  • Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. 
  • Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study. 
  • Phosphate: a novel cardiovascular risk factor. 
  • Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. 
  • Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study. 
  • Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). 
  • Plasma FGF23 levels increase rapidly after acute kidney injury. 
  • Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? 
  • Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. 
  • Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. 
  • Pruning the ricket thicket. 
  • R-spondin1 tips the balance in sex determination. 
  • Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. 
  • Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. 
  • Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. 
  • Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. 
  • Randomized trial of intravenous iron-induced hypophosphatemia. 
  • Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. 
  • Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. 
  • Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. 
  • Regulated addition of new myocardial and epicardial cells fosters homeostatic cardiac growth and maintenance in adult zebrafish. 
  • Reiterative roles for FGF signaling in the establishment of size and proportion of the zebrafish heart. 
  • Response to Letter to the Editor: "Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function". 
  • Role for ETS domain transcription factors Pea3/Erm in mouse lung development. 
  • Roles for Fgf signaling during zebrafish fin regeneration. 
  • Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. 
  • Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. 
  • SCN5A variant that blocks fibroblast growth factor homologous factor regulation causes human arrhythmia. 
  • SHP-2 is required for the maintenance of cardiac progenitors. 
  • Second chances in mineral metabolism. 
  • Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. 
  • Serum FGF23 levels in normal and disordered phosphorus homeostasis. 
  • Serum levels of fibroblast growth factor 23 are elevated in patients with active Lupus nephritis. 
  • Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. 
  • Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos. 
  • Specific blockade of basic fibroblast growth factor gene expression in endothelial cells by antisense oligonucleotide. 
  • Specification of epibranchial placodes in zebrafish. 
  • Sphingosine-1-phosphate signaling regulates lamellipodia localization of cortactin complexes in endothelial cells. 
  • Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks. 
  • Stimulation of endothelial cell prostacyclin release by retina-derived factors. 
  • Structural analyses of Ca²⁺/CaM interaction with NaV channel C-termini reveal mechanisms of calcium-dependent regulation. 
  • Sugar-sweetened beverage intake associations with fasting glucose and insulin concentrations are not modified by selected genetic variants in a ChREBP-FGF21 pathway: a meta-analysis. 
  • Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. 
  • Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. 
  • Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. 
  • The BMP antagonists Chordin and Noggin have essential but redundant roles in mouse mandibular outgrowth. 
  • The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans. 
  • The biomarker niche for fibroblast growth factor 23 testing in CKD. 
  • The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. 
  • The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed? 
  • The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. 
  • The role of chordin/Bmp signals in mammalian pharyngeal development and DiGeorge syndrome. 
  • The role of peptide growth factors in epithelial ovarian cancer. 
  • Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner. 
  • Tissue interactions pattern the mesenchyme of the embryonic mouse lung. 
  • Transient laminin beta 1a Induction Defines the Wound Epidermis during Zebrafish Fin Regeneration. 
  • Tumor-induced osteomalacia masking primary hyperparathyroidism. 
  • Twist is an integrator of SHH, FGF, and BMP signaling. 
  • Unrelated developmental neurotoxicants elicit similar transcriptional profiles for effects on neurotrophic factors and their receptors in an in vitro model. 
  • Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease. 
  • Update on fibroblast growth factor 23 in chronic kidney disease. 
  • Updating the Wnt pathways. 
  • Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. 
  • rHuKGF ameliorates symptoms in DSS and CD4(+)CD45RB(Hi) T cell transfer mouse models of inflammatory bowel disease. 
  • αKlotho: FGF23 coreceptor and FGF23-regulating hormone. 
• 

  Keywords of People

  • Adkins, Deanna Wilson, Associate Professor of Pediatrics, Pediatrics, Endocrinology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Hogan, Brigid L. M., George Barth Geller Distinguished Professor for Research in Molecular Biology, Cell Biology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology